Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.55
+$0.24 · +5.57%
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Previous close
$4.55
+$0.24 · +5.57%
After-hours
$4.45
−$0.10 · -2.20%
Sep 11, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Day range
Current $4.55
52-week range
Current $4.55
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
26
Expensive
Sentiment
53
Mixed
Risk
69
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Day range
Current $4.55
52-week range
Current $4.55
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | — | — | — | 26K USD |
| Cost of goods sold | — | — | — | 21.57K USD |
| Gross profit | — | — | — | 4.43K USD |
| Research and development | 2.99M USD | — | — | — |
| Selling, general, and administrative | 1.25M USD | 290.39K USD | 19.3K USD | 24.66K USD |
| Operating expenses | 4.24M USD | 365.06K USD | 19.3K USD | 24.66K USD |
| Interest expense | 8.54K USD | — | — | — |
| Depreciation and amortization | — | — | 1.82K USD | 21.16K USD |
| Operating income | −4.24M USD | −365.06K USD | −19.3K USD | −20.23K USD |
| Net income | −4.23M USD | −361.51K USD | −19.2K USD | −20.23K USD |
Company facts updated Sep 12, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 20, 2026 | 1:20 | — | — |
Effective Aug 20, 2026
1:20
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
